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Abstract
Background: Use of different methods for assessing the efficacy of artemisinin-based combination
antimalarial treatments (ACTs) will result in different estimates being reported, with implications
for changes in treatment policy.
Methods: Data from different in vivo studies of ACT treatment of uncomplicated falciparum
malaria were combined in a single database. Efficacy at day 28 corrected by PCR genotyping was
estimated using four methods. In the first two methods, failure rates were calculated as
proportions with either (1a) reinfections excluded from the analysis (standard WHO per-protocol
analysis) or (1b) reinfections considered as treatment successes. In the second two methods, failure
rates were estimated using the Kaplan-Meier product limit formula using either (2a) WHO (2001)
definitions of failure, or (2b) failure defined using parasitological criteria only.
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Results: Data analysed represented 2926 patients from 17 studies in nine African countries. Three
ACTs were studied: artesunate-amodiaquine (AS+AQ, N = 1702), artesunate-sulphadoxine-
pyrimethamine (AS+SP, N = 706) and artemether-lumefantrine (AL, N = 518).
Using method (1a), the day 28 failure rates ranged from 0% to 39.3% for AS+AQ treatment, from
1.0% to 33.3% for AS+SP treatment and from 0% to 3.3% for AL treatment. The median [range]
difference in point estimates between method 1a (reference) and the others were: (i) method 1b
= 1.3% [0 to24.8], (ii) method 2a = 1.1% [0 to21.5], and (iii) method 2b = 0% [-38 to19.3].
The standard per-protocol method (1a) tended to overestimate the risk of failure when compared
to alternative methods using the same endpoint definitions (methods 1b and 2a). It either
overestimated or underestimated the risk when endpoints based on parasitological rather than
clinical criteria were applied. The standard method was also associated with a 34% reduction in the
number of patients evaluated compared to the number of patients enrolled. Only 2% of the sample
size was lost when failures were classified on the first day of parasite recurrence and survival
analytical methods were used.
Conclusion: The primary purpose of an in vivo study should be to provide a precise estimate of
the risk of antimalarial treatment failure due to drug resistance. Use of survival analysis is the most
appropriate way to estimate failure rates with parasitological recurrence classified as treatment
failure on the day it occurs.
Background
Studies of antimalarial drug efficacy remain the primary
source of evidence for treatment policy decisions. How
these studies should be conducted and interpreted is still
a subject for debate. Contentious methodological issues
include length of follow-up after treatment, whether to
use clinical or parasitological outcomes and which analyt-
ical methods are the most appropriate [1-4]. Study designs
and data analysis vary; this makes combining and com-
paring data difficult. The World Health Organization
(WHO) has made considerable efforts to standardize
methods for the assessment of antimalarial drug efficacy
over the last 40 years but these have changed several
times, in line with the prevailing opinion at the time. The
first in vivo test was developed in 1965 and was designed
for the assessment of chloroquine efficacy against falci-
parum malaria using strictly defined parasitological end
points. The protocol was revised in 1967 and 1972, with
patients followed up for 28 days and kept in a mosquito-
free environment to prevent re-infection. Subsequent
modifications to the protocol in 1996 permitted a shorter
length of follow-up of 14 days in areas of high transmis-
sion, where the main endpoint changed from parasitolog-
ical clearance without subsequent recrudescence to
adequate clinical response, i.e. a patient in whom para-
sites reappeared without symptoms was still regarded as
'cured'. In 2001, the length of follow-up was increased to
28 days in areas of intense transmission, if PCR genotyp-
ing was available, and the concept of late treatment failure
incorporating clinical or parasitological failures was intro-
duced. Asymptomatic patients with parasitological failure
were followed from the day of reappearance to the last day
of follow-up when they were treated if parasites were still
present [5-7]. In a more recent document, 'Susceptibility
of Plasmodium falciparum to antimalarial drugs', an update
of the therapeutic efficacy test and modification of the
protocol have been proposed with late parasitological fail-
ure defined as "presence of parasitaemia between day 7
and day 28 with temperature ‹37.5°C, without the patient
previously meeting any of the criteria of early treatment
failure or late clinical failure" [8]. Definitions of end-
points are summarized in Figure 1.
Analysis of efficacy data
The recommended method for analysis of efficacy data
changed in the 2001 WHO protocol to survival analysis.
In the 2001 report, the life-table method is mentioned
and, in the more detailed 2003 guidelines, there is an
annex enabling users to calculate Kaplan-Meier survival
curves by hand. In order for data to be comparable with
earlier results, it was advised that "data [also] be analysed
using the traditional 'per-protocol' approach", i.e. failure
rates expressed as proportions with exclusion of patients
lost from the study for any reason other than genotyping-
confirmed recrudescence before the last day of follow-up.
An Excel™ programme was developed to enable users to
get their results analysed with per-protocol and Kaplan-
Meier methods. In practice, survival analysis has not been
used widely, but consensus appears to be growing that it
is the method of choice [1,4,9].
Polymerase chain reaction genotyping
PCR genotyping allows the reappearance of parasites dur-
ing follow-up to be classified as a new or recrudescent
infection. However the technique is not without its limi-
tations. Methods are not standardized with different labo-
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ratories using different numbers of genotypic markers and
different methods of interpretation [10]. Distinguishing a
new from a recrudescent infection is particularly challeng-
ing in areas of high transmission where multiple genotype
infections are common [11]. Identification of an identical
genotype during follow-up is not absolute proof of recru-
descence just as identification of a different genotype
could indicate recrudescence of a previously undetected
minority genotype. The WHO has recommended since
2003 that for data analysis "re-infections (as well as PCR
unclassifiable results) be classified as involuntary with-
drawals" and, therefore, excluded from the analysis.
Implications of using different analytical methods
The differences which may result from use of different
methods of analysis are important because results of in
vivo studies using the WHO protocol are used to guide
changes in treatment policy. Current recommendations
(WHO 2006) are that a new antimalarial drug combina-
tion should be 95% efficacious when deployed and
change should be considered when efficacy falls to 90%
[12].
Data sources
Since 2002, Epicentre/Médecins sans Frontières and the
Department of Medicine, San Francisco General Hospital,
University of California, San Francisco (UCSF), in part-
nership with Ministries of Health or Universities in a
number of African countries have conducted studies of
the efficacy of artemisinin-based combination regimens.
All studies underwent ethical review and were approved
by the relevant national authorities [13-26].
Study objectives
These data were combined for this analysis with the fol-
lowing objectives-
(a) to examine the effect of using different definitions of
treatment failure and methods of analysis on estimates of
PCR-corrected failure rates.
(b) to describe the utility of PCR genotyping to classify
parasite recurrences in in vivo studies.
Methods
Criteria for inclusion or exclusion of data
Studies were included if the treatment given was a super-
vised therapeutic regimen of three days of an artemisinin
derivative combined with another antimalarial, and com-
plied with the WHO 2001 guidelines, with follow-up for
at least 28 days and PCR genotyping to distinguish re-
infections from recrudescences.
Overview of design of studies and methods
In brief, children aged 6–59 months were eligible for
enrolment if they had P. falciparum mono-infection (den-
sity threshold at entry varying with study site from a min-
imum of 500 to 2,000/μL up to a maximum of 100,000 or
200,000/μL), met none of the criteria for severe malaria,
no reported hypersensitivity to the study drug, no serious
Classification of efficacy endpoints (WHO, 2001)Figure 1
Classification of efficacy endpoints (WHO, 2001).
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concomitant febrile illness and consent given by accom-
panying caregivers. Subjects were re-assessed clinically
and parasitologically on days 1, 2, 3, 7, 14, 21 and 28, or
any day in-between in case of illness. In the studies con-
ducted by Epicentre/MSF, when asymptomatic parasitae-
mia occurred after day 3, children were monitored closely
and administered a rescue antimalarial (quinine), if fever
was measured in the clinic, or if they were still parasitae-
mic without symptoms on day 28. In the UCSF collabora-
tive studies cases of recurrent parasitaemia with a history
of fever were treated.
PCR genotyping methods
PCR genotyping was used to classify parasite recurrences
occurring after day 14 of follow up. All recurrences occur-
ring on or before day 14 were considered to be recrudes-
cent infections. Genotyping was done at different
laboratories that used different extraction methods, prim-
ers and reaction conditions (Table 1). For the Epicentre/
MSF studies, cases in which the post-treatment sample
featured all or some of the pre-treatment alleles were con-
sidered recrudescent infections; cases in which pre- and
post-treatment genotypes were entirely different were con-
sidered as new infections. This approach was modified to
classify recurrences of parasitaemia in the UCSF collabo-
rative studies as follows:
(i) PCR outcomes defined as "recrudescence + re-infec-
tion" were reclassified as recrudescence if more the half
the alleles on the day of failure were present on day 0 or
as new infections for the remainder (Kampala, Uganda).
(ii) PCR outcomes defined as "recrudescence + re-infec-
tion" were classified as new infections (Apac, Arua, Tororo
2004, Jinja, Uganda).
(iii) PCR outcomes defined as "recrudescence + re-infec-
tion" were classified as new infections. MSP1 was also
done for patients defined as "recrudescence" by MSP2.
The final classification of recrudescence required that all
of the alleles on the day of failure had to be present on day
0 for both MSP2 and MSP1 (Tororo 2005, Uganda).
(iv) MSP2, MSP1 and four microsatellites were used for all
LCF and LPFs. To be classified as a recrudescence there
had to be at least one allele present on the day of failure
which was present on day 0 for all six loci (Burkina Faso
2005).
Data analysis
Databases were imported into Stata 9.0 (Stata Corp.,
Texas, USA) and the variables of interest selected which
were recoded according to a pre-determined list. Individ-
ual databases were verified against existing study reports if
available. Discrepancies were resolved by consultation
with the study principal investigators. Individual data-
bases were merged into a single database for analysis.
Evaluation of PCR genotyping methods
PCR genotyping results for children with a parasite recur-
rence after day 14 were classified as either resolved by PCR
(recrudescence or re-infection), or unresolved by PCR,
and the reason recorded (missing sample, failure to
extract DNA, indeterminate result).
The use-effectiveness of the PCR genotyping method was
assessed, defined as the number of children with parasite
recurrence resolved by PCR divided by the total number of
children with recurrences after day 14 [27].
Efficacy analyses
Four different analyses were done. Figure 2 presents the
population selected and the methods used for each analy-
sis. The populations differ depending on both the defini-
tion of failure and the analytical method used. Efficacy
results are presented as point estimates for each drug in
each study without making comparisons between treat-
ment arms in the same study. Patients wrongly rand-
omized, who did not meet study inclusion criteria were
excluded from all analyses. Withdrawals for other reasons
were dealt with in different ways depending on the analyt-
ical method used as explained below. Failure rates were
calculated as proportions (methods 1a and 1b) or esti-
mated using survival analytical methods (methods 2a and
2b) as follows-
(i) Day 28 failure rates calculated as proportions using a
per-protocol dataset-
Patients with no outcome on day 28 (losses to follow up
and withdrawals) and patients with recurrence unresolved
by PCR were excluded from these analyses. New infec-
tions during the follow-up were treated in 2 ways:
• Method 1a: individuals with new infections excluded
from the analysis. This is the standard per-protocol analy-
sis reported by most investigators following the WHO
protocol and for convenience will be referred to as the
"WHO per protocol method" to indicate failure rates cal-
culated as proportions and endpoints defined as in the
WHO (2001) protocol.
• Method 1b: all PCR-confirmed new infections re-classi-
fied as successes (ACPR).
(ii) Day 28 failure rates estimated by the Kaplan-Meier
product limit formula (survival analysis) using the dataset
of correctly randomized patients -
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Table 1: Laboratories performing PCR genotyping with assessment of PCR use-effectiveness in 17 in vivo studies of antimalarial drug 
efficacy
Year Country
 & Site
Laboratory Method used N Unresolved
by PCR
n
Resolved
by PCR
n
PCR Use-
effectiveness
 [95%CI]
recurr.
after
  day14
2002 Zambia, Maheba Rouen France msp2 43 3 40 93.0
[80.9–98.5]
2003 Angola, Kuito IMT Antwerp msp1+msp2 8 0 8 100.0
[63.1–100.0]
2003 DRC, Boende IMT Antwerp msp1+msp2 +glurp 78 10 68 87.2
[77.7–93.7]
2003 S Sudan, Nuba Wellcome Trust/Medical 
College of Malawi
msp1+msp2 54 15 39 72.2
[58.3–83.5]
2003 Uganda, Amudat Epicentre Mbarara msp1+msp2 +glurp 73 4 69 94.5
[86.6–98.5]
2003 Uganda, Jinja UCSF msp2 27 2 25 92.6
[75.7–99.1]
2003 Uganda, Kampala UCSF msp2 14 0 14 100.0
[76.8–100.0]*
2004 Angola, Caala Mbarara University msp1+msp2 +glurp 6 2 4 66.7
[22.3–95.7]
2004 Congo, Kindamba SMRU msp1+msp2 +glurp 60 24 36 60.0
[46.5–72.4]
2004 DRC, Kabalo Epicentre Mbarara msp1+msp2 +glurp 10 1 9 90.0
[55.5–99.7]
2004 Guinea, Dabola Epicentre Mbarara msp1+msp2 +glurp 14 1 13 92.9
[66.1–99.8]
2004 Sierra Leone, Kailahun Paris, Avicenne msp1+msp2 65 1 64 98.5
[91.7–100.0]
2004 Uganda, Apac UCSF msp2 76 3 73 96.0
[88.9–99.2]
2004 Uganda, Arua UCSF msp2 61 4 57 93.4
[84.1–98.2]
2004 Uganda, Tororo UCSF msp2 120 3 117 97.5
[92.9–99.5]
2005 Burkina Faso, Bobo-
Dioulasso
UCSF msp1 +msp2 + 4 
microsatellites
24 0 24 100
[85.7–100]*
2005 Uganda, Tororo UCSF msp1+msp2 209 4 205 98.1
[95.2–99.5]
TOTAL 942 77 865
Weighted average 
[CI 95]
91.8 [89.9–93.4]
Median [range] 93.4 [60–100]
Use-effectiveness = number of children with parasite recurrence resolved by PCR/total number of children with recurrences after day 14.
* One sided 97.5% CIs have been calculated
IMT Institut de Médecine Tropicale Antwerp
KEMRI Kenya Medical Research Institute
SMRU Shoklo Malaria Research Unit, Thailand
UCSF University of California, San Francisco
msp1 merozoite surface protein 1
msp2 merozoite surface protein 2
glurp glutamate rich protein
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Losses to follow-up and withdrawals were included in this
analysis and were censored on the last day seen. This anal-
ysis was done using two different definitions of failure -
• Method 2a: The definition of failure included all early
treatment failures plus late treatment failures (LCFs or
LPFs classified on day 28 as defined by WHO (2001)).
Patients classified as LCF with a reinfection were censored.
Patients with unresolved PCR results were excluded (n =
74).
• Method 2b: The definition of failure included all early
treatment failures plus late treatment failures (LTF), which
were defined on day 7 in patients whose initial parasitae-
mia had not cleared, or on the first day of any parasite
recurrence during follow-up (including day 7 or earlier),
irrespective of symptoms. For this analysis, patients with
reinfections were censored on the day of parasite reap-
pearance and those with indeterminate or missing geno-
typing results were censored on the last visit with a
negative malaria smear result documented [4]. The date
the PCR was taken was not the date of parasite recurrence
in all cases and genotyping results were missing for a
small number of participants (N = 16) because their recur-
rent parasites had resolved without further treatment by
day 28, and thus using the WHO (2001) classification
they had been classified as ACPRs at the time the study
was done. These patients were censored at the time of the
previous visit when the malaria smear was negative.
Effect of method of assessment of sample size evaluated
The numbers of patients included in the four efficacy anal-
yses were compared and the percentage of patients
excluded from the enrolled patient population calculated
for each method (Figure 2).
Results
Out of 21 studies in which 4,684 patients were in an ACT
treatment arm, 17 were included in the analysis represent-
ing a total of 2926 children treated with an ACT. Reasons
for excluding studies or patients were major deviations
from the WHO protocol (1257 patients), patients greater
than five years of age enrolled (335), or unacceptable lab-
oratory quality control results (166 patients in one study).
Most studies (12/17) were in areas described as hyperen-
demic for malaria.
The most commonly studied ACT was artesunate-amodi-
aquine (AS+AQ) (15 sites, 1,702 children), followed by
artesunate-sulphadoxine-pyrimethamine (AS+SP) (eight
sites, 706 children) and artemether-lumefantrine (AL)
(four sites, 518 children).
Summary of different analysesFigure 2
Summary of different analyses. Notes: Shaded boxes represent patients excluded from the analyses. Analysable popula-
tions – Figures in parentheses represent the % patients excluded from the enrolled patient population using each method of 
analysis.
 
Method 1: 
Day28 failure rates 
calculated as proportions
Method 2: 
Day28 failure rates estimated 
by survival methods
All enrolled 
patients
2926
Major protocol violations
Patients with no outcome
on Day 28:
 - Lost to follow-up
 - Withdrawals
Patients with no follow-up
Method 1a (WHO per-
protocol analysis) Method 1b Method 2a (WHO 2001) Method 2b 
Unresolved PCR Unresolved PCR Unresolved PCR
Reinfections
Analysable population Analysable population Analysable population Analysable population
1928 (- 34%) 2662 (- 9%) 2794 (-4.5%) 2871 (-1.9%)
Failure < d14 => failure Failure < d14 => failure Failure < d14 => failure All late failure classified on day of 
Recrudescence => failure Recrudescence => failure Recrudescence => failure parasite recurrence
Reinfection => success Reinfection => censored Failure < d14 => failure
LFU and withdrawals censored Recrudescence => failure
on last day seen Reinfection => censored
LFU and withdrawals censored 
on last day seen
Unresolved PCR censored 
on previous visit
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Description of treatment outcomes according to the WHO 
2001 classification
There were four early treatment failures (ETF), 635 late
clinical failures (LCF) and 376 late parasitological failures
(LPF). Only 2% patients were lost to follow-up. There
were 127 (4%) withdrawals in all studies. The reasons for
withdrawal were repeated vomiting (20/127), taking
another drug with antimalarial activity (23/127), con-
comitant disease (23/127), withdrawal of consent (7/
127), other protocol violation (48/127), death (1/127)
and unknown (5/127).
Results of efficacy analyses
Efficacy results are summarized in Tables 2, 3 and 4. Using
method 1a (per protocol) day 28 failure rates ranged from
0% to 39.3% for AS+AQ treatment (Table 2), from 0% to
3.3% for AL treatment (Table 3) and from 1.0% to 33.3%
for AS+SP treatment (Table 4). Failure rates exceeded 10%
at 7/15 sites for AS+AQ, 0/4 sites for AL and 4/8 sites for
AS+SP. The upper 95% CI exceeded 10% at 11 sites for
AS+AQ, no sites for AL and 6 sites for AS+SP.
Using method 1a as the reference analytical method, the
median [range] differences between these results and
those obtained using method 1b were 1.3% [0–24.8],
method 2a 1.1% [0–21.5] and method 2b 0% [-38–19.3].
Classifying patients as failures on day 7 if initial parasitae-
mia had not cleared, or on the first day of parasite recur-
rence, regardless of symptoms (method 2b) increased the
number of treatment failures (uncorrected by genotyping)
by 75, from 1015 to 1090 but it should be noted that the
majority of these patients (50) were from one site
(Boende).
Effect of method of assessment on sample size evaluated
Figure 2 illustrates how the choice of definitions and
methods for assessment of efficacy (corrected by PCR)
Table 2: Day 28 failure rates estimated by four methods – AS+AQ treatment
Day 28 failure rates
% [CI95%]
Year Country &
 Site
Method 1a
(per protocol)
Method 1b Method 2a
(WHO 2001)
Method 2b
2003 Angola, Kuito 1.3 1.2 1.2 1.2
[0–6.8] [0–6.4] [0.2–8.3] [0.2–8.1]
2003 DRC, Boende 18.3 14.1 15.3 56.3
[9.5–30.4] [7.2–23.8] [8.7–25.9] [45.8–67.4]
2003 S Sudan, Nuba 7.3 5.6 6.2 8.4
[2.0–17.6] [1.5–12.6] [2.4–15.7] [3.9–18.0]
2003 Uganda, Amudat 22.6 8.8 10.4 21.4
[9.6–41.1] [3.6–17.2] [4.9–21.1] [14.0–31.8]
2003 Uganda, Jinja 7.9 6.5 7.0 12.2
[3.2–15.7] [2.7–13.0] [3.4–14.1] [7.2–20.1]
2003 Uganda, Kampala 4.9 4.1 4.3 4.3
[1.0–13.7] [0.9–11.5] [1.4–12.8] [1.4–12.9]
2004 Angola, Caala 0 0 0 1.5
[0–6.0]* [0–5.7]* [0–5.8]* [0.2–10.4]
2004 Congo, Kindamba 6.0 4.8 4.8 6.4
[1.6–14.6] [1.3–11.9] [1.8–12.2] [2.9–13.7]
2004 DRC, Kabalo 0 0 0 4.4
[0–8.4]* [0–7.9]* [0–7.9]* [1.1–16.3]
2004 Guinea, Dabola 1.0 0.9 0.9 0.9
[0–5.3] [0–5.1] [0.1–6.5] [0.1–6.5]
2004 S Leone, Kailahun 27.0 15.4 19.0 20.5
[16.6–39.6] [9.3–23.6] [12.3–28.8] [13.5–30.5]
2004 Uganda, Apac 24.5 15.0 15.7 15.9
[16.2–34.4] [9.8–21.7] [10.7–22.7] [10.8–23.1]
2004 Uganda, Arua 28.7 19.9 20.0 20.0
[20.4–38.2] [13.9–27.0] [14.5–27.2] [14.6–27.0]
2004 Uganda, Tororo 39.3 14.5 17.8 20.0
[27.1–52.7] [9.5–20.9] [12.1–25.8] [13.6–28.9]
2005 Uganda, Tororo 13.9 5.5 5.4 5.9
[6.9–24.1] [2.6–9.8] [2.9–9.8] [3.3–10.4]
*one-sided 97.5% CIs
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affected the number of patients assessed in the final effi-
cacy evaluation. The biggest reduction in sample size of
34% occurred using the per-protocol analysis (method
1a). The smallest reduction in sample size occurred when
method 2b was applied.
PCR findings
Recurrence of parasitaemia between days 14 and 28
occurred in 942 (32%) children. Of these, 77 (8.3%)
patients could not be classified because: (i) 18 samples
were missing, (ii) in 31 samples it was not possible to
amplify any parasite DNA, (iii) DNA was amplified but no
classification could be given (indeterminate) in 26 sam-
ples, and (iv) the reason was unknown for two samples.
A total of 865 recurrences were categorized following PCR
genotyping with: (i) 118 (12.5%) classified as recrudes-
cent, (ii) 734 (77.9%) as re-infections, and (iii) 13 (1.4%)
as recrudescence + re-infection, regarded as recrudescent
for the purposes of this analysis. The use-effectiveness was
91.8% (865/942) and ranged from 60.0% for Congo-Kin-
damba to 100.0% for Angola-Kuito and Uganda-Kampala
and Bobo-Dioulasso, Burkina Faso (Table 1).
Discussion
This analysis of pooled data has shown that failure rates
can vary markedly depending on the analytical method
used. The point estimates of failure calculated using the
per-protocol analysis compared to methods 1b and 2a
were the highest. This systematic overestimation is attrib-
utable to the effect of excluding patients with new infec-
Table 3: Day 28 failure rates estimated by four methods – AL treatment
Day 28 failure rates
% [CI95%]
Method 1a
(per protocol)
Method 1b Method 2a
(WHO 2001)
Method 2b
2004 Angola, Caala 0 0 0 0
[0–6.1]* [0–6.0]*
2004 Congo, Kindamba 1.2 1.1 1.1 1.0
[0–6.2] [0–6.0] [0.2–7.3] [0.1–6.8]
2005 Burkina Faso, Bobo-Dioulasso 3.2 2.8 2.8 2.8
[0.9–8.1] [0.8–6.9] [1.1–7.3] [1.1–7.3]
2005 Uganda, Tororo 3.3 1.6 1.8 1.8
[0.7–9.3] [0.3–4.7] [0.6–5.4] [0.6–5.7]
*one-sided 97.5% Cis
Table 4: Day 28 failure rates estimated by four methods – AS+SP treatment
Day 28 failure rates
Year Country &
 Site
Method 1a
(per protocol)
Method 1b Method 2a
(WHO 2001)
Method 2b
2002 Zambia, Maheba 21.7 13.2 15.4 29.8
[10.9–36.4] [6.5–22.9] [8.6–26.8] [20.5–42.1]
2003 Angola, Kuito 1.2 1.2 1.1 2.3
[0–6.6] [0–6.4] [0.2–7.8] [0.6–8.8]
2003 DRC, Boende 33.3 25.3 27.3 59.5
[21.9–46.3] [16.4–36.0] [18.7–38.9] [48.8–70.5]
2003 S Sudan, Nuba 10.3 8.3 8.6 10.5
[3.9–21.2] [3.1–17.3] [4.0–18.2] [5.4–19.9]
2003 Uganda, Amudat 7.9 6.8 6.8 8.0
[2.6–17.5] [2.2–15.1] [2.9–15.5] [3.7–16.9]
2004 Congo, Kindamba 11.1 10.0 10.1 11.0
[4.9–20.7] [4.4–18.8] [5.2–19.2] [5.9–20.2]
2004 DRC, Kabalo 2.3 2.0 2.0 11.8
[0–12.3] [0–10.8] [0.3–13.4] [5.5–24.4]
2004 Guinea, Dabola 1.0 0.9 0.9 2.8
[0–5.5] [0–5.2] [0.1–6.5] [0.9–8.5]
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tions from the analysis. Predictably, the magnitude of the
difference from the estimate obtained using method 1b
varied according to the number of patients re-infected
during follow-up, hence intensity of transmission and the
post-treatment prophylactic effect of the drug. In these
studies, the effect of data loss due to patient loss to follow
up (2%) and withdrawals (4%) was small over 28 days.
If the results of the survival analysis using the same defini-
tions of failure (WHO 2001) are compared to the results
of the per protocol analysis the median difference in the
point estimates for failure at day 28 was small at 1.1% but
ranged from 0 to 21.5%. Again, the difference was greater
at the sites with the highest numbers of parasite recur-
rences, whether related to transmission intensity and
more reinfections or a higher number of recrudescent
infections. The precision of those estimates generated by
the per protocol analysis was lower. Comparisons of pre-
cision cannot be made against methods 1b or 2b because
the endpoint classifications were different.
The change in definition of failure from the WHO (2001)
protocol to method 2b led to an increasing number of
patients being classified as treatment failures (uncorrected
by genotyping): 1090 compared to 1015. By classifying
patients on day 7 or on the day of recurrence rather than
by day 28 (method 2b vs. 2a), the results of the survival
analyses changed little in most of the studies but markedly
at certain sites where several patients who had been clas-
sified as ACPRs using the 2001 criteria were reclassified as
late treatment failures using the 2005 definition, e.g. the
Boende site in DRC where failure [95% CI] would have
been estimated as 15.3% [8.7–25.9] when the study was
done in 2003 and 56.3% [45.8–67.4] if it had been done
2 years later following the newer recommendations. This
was because a relatively high proportion of patients who
were still parasitaemic on days 7 (n = 29) and 14 (n = 21)
but asymptomatic had cleared their parasites by day 28
without treatment.
The methods for assessing antimalarial drug efficacy con-
tinue to evolve. The quality of the data generated by an in
vivo study depends on the study design and execution, the
quality of the laboratory and the interpretation of the gen-
otyping results. For the efficacy analysis, there is a growing
consensus that the Kaplan-Meier survival analysis is the
optimal method because it retains the maximal amount of
data for analysis and avoids the inaccurate overestimation
of failure rates that will occur when large numbers of
patients are excluded from the analysis. This overestima-
tion is likely to increase as a drug's efficacy declines with a
consequent increase in the number of recrudescences and
new infections. These results support expert opinion that
survival analysis should become the standard way of ana-
lysing data from in vivo tests and should replace the tradi-
tional per-protocol method. The per-protocol method
was associated with a 34% reduction in sample size, com-
pared to a < 10% reduction for the other methods. How-
ever, it is true that while survival analysis maximizes the
sample size, some of the patients will only have com-
pleted a trivial period of follow up. Regarding re-infec-
tions as treatment successes (method 1b) preserves the
sample size but leads to an underestimation of the failure
rate and is not recommended.
Efficacy of AS+AQ was below 90% at 7/15 sites and of
AS+SP at 4/8 sites and the lower 95% CI was below this
level at a further four and two sites, respectively. Efficacy
of AL was high in the small number of patients studied.
The reduced efficacy of AS+AQ and AS+SP could be
explained by the use of the more slowly eliminated part-
ner drug as monotherapy before and during the deploy-
ment of the combinations. An alternative explanation for
these results is different methods of classification by PCR
genotyping. The results reported here suggest that PCR
genotyping performed well as a discriminatory test inas-
much as the majority of patients were classified, but the
results are only as valid as the interpretation algorithms
used to classify them. Differences in performance were
observed between different laboratories, which did not
appear to be related to the number of markers used. PCR
outcomes defined as recrudescence + re-infection were
classified as new infections by laboratories in certain stud-
ies but not in others as described in the methods. Current
genotyping techniques, even using up to six markers, are
not sufficiently discriminatory in areas of high transmis-
sion where multiple genotype infections are common
[11]. Standardization of genotyping techniques and inter-
pretation rules should reduce this inter-laboratory varia-
tion. There is evidence from genotypic studies that re-
infections can occur before day 14 [28]. More work needs
to be done in this area and the current guidelines, stating
that only parasite recurrences occurring after this day
should be genotyped, may need to be revised.
These results support the recommendation for a mini-
mum follow-up period of 28 days in the assessment of
efficacy of ACTs, with PCR-genotyping of all recurrences
and the use of the Kaplan-Meier product-limit formula to
estimate efficacy of treatment in all correctly randomized
patients.
Accurate reporting of methods by investigators is essen-
tial, in particular definitions of endpoints and criteria for
censoring all categories of patients who do not complete
follow-up. It is recommended that the classification of
treatment failure is based on parasitological outcomes
only and that all parasitological recurrences be treated
straightaway in view of the high likelihood that patients
will go on to develop symptoms [29]. Further standardi-
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zation of definitions and analytical methods will facilitate
combining data in this critical period post ACT-deploy-
ment, allowing trends in efficacy to be monitored at a glo-
bal level [9,30].
The WHO (2001) protocol was not designed to be a com-
parative study protocol, but rather a single-arm in vivo
assessment to guide treatment policy. Such studies should
be powered to estimate the effect size with adequate pre-
cision. However, if an efficacy assessment is being done
because of a suspicion a drug is failing it makes sense to
evaluate a potential replacement at the same time in an
adequately powered, randomized, controlled trial. This
will provide good evidence to guide national programmes
in their drug selections.
Whether in vivo efficacy monitoring data should be used
as the only determinant for policy change is debatable, if
a choice of highly efficacious therapies becomes available.
When comparing treatments of similar efficacy other fac-
tors determining programmatic effectiveness become
more important to policy makers such as simplicity of the
regimen, formulation, tolerability, adherence, cost and
post-treatment prophylactic effect.
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